AFP and neoplasm: The study demonstrated that AFP <400 ng/ml, tumor number <3, tumor diameter <5 cm, or PVTT patients who received TACE + RFA treatment showed considerably higher 12-month OS rates than those who received TACE treatment (p=0.0122, p=0.0090, p=0.0112, and p=0.0071, respectively); however, both treatments contributed to similar OS rates in AFP ≥ 400 ng/ml, tumor number ≥ 3, tumor diameter ≥ 5 cm, HVTT or PVTT + HVTT patients (p=0.4208, p=0.6478, p=0.4700, p=0.6485, and p=0.6959, respectively).